Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2005 1
2006 1
2008 2
2009 3
2010 3
2011 4
2012 4
2013 7
2014 4
2015 10
2016 9
2017 1
2018 9
2019 5
2020 11
2021 12
2022 8
2023 12
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Results by year

Filters applied: . Clear all
Page 1
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept.
Vitale A, Cabibbo G, Iavarone M, Viganò L, Pinato DJ, Ponziani FR, Lai Q, Casadei-Gardini A, Celsa C, Galati G, Gambato M, Crocetti L, Renzulli M, Giannini EG, Farinati F, Trevisani F, Cillo U; HCC Special Interest Group of the Italian Association for the Study of the Liver. Vitale A, et al. Lancet Oncol. 2023 Jul;24(7):e312-e322. doi: 10.1016/S1470-2045(23)00186-9. Lancet Oncol. 2023. PMID: 37414020 Review.
Chemotherapy-induced bowel ischemia: diagnostic imaging overview.
Reginelli A, Sangiovanni A, Vacca G, Belfiore MP, Pignatiello M, Viscardi G, Clemente A, Urraro F, Cappabianca S. Reginelli A, et al. Among authors: sangiovanni a. Abdom Radiol (NY). 2022 May;47(5):1556-1564. doi: 10.1007/s00261-021-03024-9. Epub 2021 Apr 3. Abdom Radiol (NY). 2022. PMID: 33811514 Free PMC article. Review.
Non-Oncological Radiotherapy: A Review of Modern Approaches.
Nardone V, D'Ippolito E, Grassi R, Sangiovanni A, Gagliardi F, De Marco G, Menditti VS, D'Ambrosio L, Cioce F, Boldrini L, Salvestrini V, Greco C, Desideri I, De Felice F, D'Onofrio I, Grassi R, Reginelli A, Cappabianca S. Nardone V, et al. Among authors: sangiovanni a. J Pers Med. 2022 Oct 9;12(10):1677. doi: 10.3390/jpm12101677. J Pers Med. 2022. PMID: 36294816 Free PMC article. Review.
[Hepatocellular carcinoma].
Colombo M, Sangiovanni A. Colombo M, et al. Among authors: sangiovanni a. Recenti Prog Med. 2016 Jul;107(7):386-94. doi: 10.1701/2318.24934. Recenti Prog Med. 2016. PMID: 27571469 Free article. Italian.
Advanced precancerous lesions in the liver.
Di Tommaso L, Sangiovanni A, Borzio M, Park YN, Farinati F, Roncalli M. Di Tommaso L, et al. Among authors: sangiovanni a. Best Pract Res Clin Gastroenterol. 2013 Apr;27(2):269-84. doi: 10.1016/j.bpg.2013.03.015. Best Pract Res Clin Gastroenterol. 2013. PMID: 23809245 Review.
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.
Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, Nahon P, Mariño Z, Tateishi R, Minami T, Sangiovanni A, Forns X, Toyoda H, Brillanti S, Conti F, Degasperi E, Yu ML, Tsai PC, Jean K, El Kassas M, Shousha HI, Omar A, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, Murphy C, Kohla M, Masetti C, Dufour JF, Merchante N, Cavalletto L, Chemello LL, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Bielen R, Trevisani F, Cammà C, Bruix J, Cabibbo G, Reig M. Sapena V, et al. Among authors: sangiovanni a. Gut. 2022 Mar;71(3):593-604. doi: 10.1136/gutjnl-2020-323663. Epub 2021 Mar 19. Gut. 2022. PMID: 33741640 Free article.
Extranodal Lymphomas: a pictorial review for CT and MRI classification.
Reginelli A, Urraro F, Sangiovanni A, Russo GM, Russo C, Grassi R, Agostini A, Belfiore MP, Cellina M, Floridi C, Giovagnoni A, Sica A, Cappabianca S. Reginelli A, et al. Among authors: sangiovanni a. Acta Biomed. 2020 Jul 13;91(8-S):34-42. doi: 10.23750/abm.v91i8-S.9971. Acta Biomed. 2020. PMID: 32945277 Free PMC article. Review.
Predictors of non-transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection.
Pelizzaro F, Trevisani F, Simeon V, Vitale A, Cillo U, Piscaglia F, Missale G, Sangiovanni A, Foschi FG, Cabibbo G, Caturelli E, Di Marco M, Azzaroli F, Brunetto MR, Raimondo G, Vidili G, Guarino M, Gasbarrini A, Campani C, Svegliati-Baroni G, Giannini EG, Mega A, Masotto A, Rapaccini GL, Magalotti D, Sacco R, Nardone G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Pelizzaro F, et al. Among authors: sangiovanni a. Liver Int. 2023 Dec;43(12):2762-2775. doi: 10.1111/liv.15719. Epub 2023 Sep 27. Liver Int. 2023. PMID: 37753540
100 results